BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorCattrini, C.
dc.contributor.authorLozano Mejorada, R.
dc.contributor.authorConteduca, V.
dc.contributor.authorRuiz-Vico, M.
dc.contributor.authorLolkema, M. P.
dc.contributor.authorLorente, D.
dc.contributor.authorSandhu, S.
dc.contributor.authorRomero Laorden, N.
dc.contributor.authorLoriot, Y.
dc.contributor.authorAzad, A. A.
dc.contributor.authorCosta, L.
dc.contributor.authorVinceneux, A.
dc.contributor.authorKanesvaran, R.
dc.contributor.authorUrun, Y.
dc.contributor.authorPuente, J.
dc.contributor.authorAttard, G.
dc.contributor.authorMehra, N.
dc.contributor.authorDe Giorgi, U.
dc.contributor.authorOlmos Hidalgo, D.
dc.contributor.authorCastro Marcos, E.
dc.contributor.authoraffiliation[Cattrini, C.] Spanish Natl Canc Res Ctr CNIO, Prostate Canc Clin Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Lozano Mejorada, R.] Spanish Natl Canc Res Ctr CNIO, Prostate Canc Clin Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Olmos Hidalgo, D.] Spanish Natl Canc Res Ctr CNIO, Prostate Canc Clin Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Conteduca, V.] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, SC Oncol Med, Meldola, Italy
dc.contributor.authoraffiliation[De Giorgi, U.] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, SC Oncol Med, Meldola, Italy
dc.contributor.authoraffiliation[Ruiz-Vico, M.] UCL Canc Inst, Treatment Resistance Res Grp, London, England
dc.contributor.authoraffiliation[Attard, G.] UCL Canc Inst, Treatment Resistance Res Grp, London, England
dc.contributor.authoraffiliation[Lolkema, M. P.] Erasmus MC, Med Oncol, Rotterdam, Netherlands
dc.contributor.authoraffiliation[Lorente, D.] Consorcio Hosp Prov Castellon, Med Oncol Dept, Castellon De La Plana, Spain
dc.contributor.authoraffiliation[Sandhu, S.] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
dc.contributor.authoraffiliation[Azad, A. A.] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
dc.contributor.authoraffiliation[Romero Laorden, N.] Spanish Natl Canc Res Ctr CNIO, Prostate Canc Clin Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Loriot, Y.] Inst Gustave Roussy, Canc Med Dept, Villejuif, France
dc.contributor.authoraffiliation[Costa, L.] Hosp Santa Maria HSM, Med Oncol Dept, Ctr Hosp Univ Lisboa Norte CHULN, Lisbon, Portugal
dc.contributor.authoraffiliation[Vinceneux, A.] Ctr Leon Berard, Dept Med Oncol, Lyon, France
dc.contributor.authoraffiliation[Kanesvaran, R.] Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore
dc.contributor.authoraffiliation[Urun, Y.] Ankara Univ, Sch Med, Dept Med Oncol, Ankara, Turkey
dc.contributor.authoraffiliation[Puente, J.] Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Dept Med Oncol, CIBERONC, Madrid, Spain
dc.contributor.authoraffiliation[Mehra, N.] Radboud Univ Nijmegen, Med Ctr, Dept Oncol, Nijmegen, Belgium
dc.contributor.authoraffiliation[Castro Marcos, E.] Hosp Univ Virgen de la Victoria, Med Oncol, Malaga, Spain
dc.contributor.authoraffiliation[Castro Marcos, E.] Inst Invest Biomed Malaga, Malaga, Spain
dc.contributor.funderBiomedical Research Institute of Malaga/Andalusian Public Foundation for Malaga Research in Biomedicine and Health (IBIMA/FIMABIS) Spanish National Cancer Research Centre (CNIO)
dc.date.accessioned2025-01-07T15:10:17Z
dc.date.available2025-01-07T15:10:17Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.2086
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420420836/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26933
dc.identifier.wosID573469100689
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.numberS547-S548
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleBRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía